Il2-IRES-Venus-Luc
Nomenclature
C57BL/6Smoc-Il2em1(Venus-Luci)Smoc
Cat. NO.
NM-KI-18057
Strain State
Embryo cryopreservation
Gene Summary
Gene Symbol
IL2
Model Description
Validation Data
Fig1.Hepa1-6 tumor volumes in Il2-Venus-Luci reporter mice treated or not with anti-PD-1 mAb. Arrows indicate treatment days.
Fig2. In vivo imaging validation of Hepa1-6 tumors in Il2-Venus-Luci reporter mice treated or not with anti-PD-1 mAb.
In PBS treated group, the IL2 signal increased as the tumor development, which indicated an inflamed immune environment. In the PD1 mAb treated group, the IL2 signal is enhanced, especially at day 21.
Fig3. IL2 signal in ventral position of Il2-Venus-Luci reporter mice.
IL2 signal from abdomen is higher in PD1 treated mice than control mice on day 21. The signal should be produced by immune cells in mesenteric lymph nodes.
Fig4. Tissue IL2 signal in the Il2-Venus-Luci reporter mice at termination.
Tumor draining lymph node(TDLN) from PD1 treated mice have significantly higher IL2 signal than control mice. While tumor and spleen showed lowered or comparable IL2 signal compared to control mice.
The data is provided by Crownbio.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
